Baricitinib may effectively treat oral lichen planus.
July 2024 in “Journal of Investigative Dermatology” OR101 may effectively treat atopic dermatitis and similar skin conditions.
7 citations
,
January 2017 in “Biological & Pharmaceutical Bulletin” Certain compounds from Panax ginseng can block proteins that affect hair growth, potentially helping treat hair loss.
3 citations
,
May 2023 in “Clinical drug investigation” JAK inhibitors for alopecia areata are linked to minor side effects like headache and acne, but not to an increased risk of serious adverse events.
July 2025 in “Journal of Investigative Dermatology” Baricitinib stops hair loss and promotes regrowth in alopecia areata.
March 2025 in “International Journal of Trichology” Janus kinase inhibitors may effectively treat resistant scalp conditions like folliculitis decalvans and dissecting cellulitis.
March 2026 in “JMIR Dermatology” Interest in JAK inhibitors for alopecia areata increased significantly after FDA approval, highlighting the need for patient education.
January 2026 in “Skin Health and Disease” Irish dermatologists use JAK inhibitors for alopecia areata but want standardized treatment guidelines.
January 2016 in “Hair transplant forum international” Topical JAK inhibitors may help treat hair loss.
JAK inhibitors effectively regrow hair in children with alopecia areata and are safe to use.
701 citations
,
August 2014 in “Nature medicine” Alopecia areata can be reversed by JAK inhibitors, promoting hair regrowth.
49 citations
,
August 2018 in “International Journal of Dermatology” Topical JAK inhibitors may help treat alopecia universalis by promoting hair regrowth.
October 2017 in “Institutional Repositories DataBase (IRDB)” Polyacetylene compounds from Panax ginseng may slow hair growth.
August 2021 in “Revista Colombiana de Reumatología/Revista Colombiana de Reumatologia” Janus kinase inhibitors may effectively treat severe alopecia areata unresponsive to other treatments.
New pyridine compounds effectively inhibit GSK3, a diabetes treatment target.
4 citations
,
June 2023 in “Frontiers in immunology” JAK inhibitors help hair regrowth in alopecia areata but have a high risk of side effects.
4 citations
,
January 2025 in “JAAD reviews.” Janus kinase inhibitors are promising for treating scarring alopecia, but more research is needed for safety and personalized treatments.
2 citations
,
May 2024 in “Expert Opinion on Drug Safety” Infections during JAK inhibitor treatment for alopecia areata are usually manageable and rarely stop treatment permanently.
69 citations
,
September 2013 in “American Journal of Alzheimer s Disease & Other Dementias®” Snakin-Z from jujube fruits may help treat Alzheimer's due to its enzyme inhibition and antioxidant properties.
June 2025 in “British Journal of Dermatology” Irish dermatologists urgently need guidelines for using JAK inhibitors in treating alopecia areata.
2 citations
,
May 2025 in “Archives of Dermatological Research” JAK inhibitors do not increase cancer risk in severe alopecia areata compared to traditional treatments.
June 2024 in “International Journal of Dermatology” Upadacitinib may effectively treat resistant lichen planopilaris.
November 2025 in “Mendeley Data” JAK inhibitors can be safely used for alopecia areata in patients with latent hepatitis B or stable tuberculosis with proper monitoring.
November 2025 in “Mendeley Data” JAK inhibitors can be safely used in alopecia areata patients with latent hepatitis B or tuberculosis, with proper monitoring.
Baricitinib is more effective than tofacitinib for hair regrowth in alopecia patients.
71 citations
,
May 2024 in “New England Journal of Medicine” Ruxolitinib may effectively treat APS-1 by reducing harmful immune responses.
7 citations
,
August 2023 in “Journal of the American Academy of Dermatology” JAK inhibitors offer new hope for treating severe alopecia areata.
Interest in JAK inhibitors for hair loss increased significantly after media coverage and FDA approval.
37 citations
,
August 2022 in “Frontiers in pharmacology” Oral JAK inhibitors are effective and safe for treating alopecia areata but may need ongoing use to keep results.
January 2010 in “Yearbook of Endocrinology” Two new compounds can block androgen receptor activity in different ways and may lead to new treatments for androgen-related diseases.